Price
No data yet.
Social Signal Score
Analyst Ratings
52 analystsRevenue
$6.59B+132.58%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin A. Lobo
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 56,000
- Beta
- 0.77
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 4.38
Financials
Revenue
$6.59B+132.6%Net Income
$1.28B+259.4%EBITDA
$1.56B+175.8%Free Cash Flow
$1.06B+182.4%EPS (diluted)
$3.30+251.1%Shares Outstanding (diluted)
386.00M+1.8%Operating Expenses
$2.66BCash & Debt
$3.48BReturn of Capital
$337.00MRevenue by Segment (annual)
$25.12BDividend per Share
$0.88Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.12B | $3.25B | $8.49 |
| 2024 | $22.59B | $2.99B | $7.86 |
| 2023 | $20.50B | $3.17B | $8.34 |
| 2022 | $18.45B | $2.36B | $6.23 |
| 2021 | $17.11B | $1.99B | $5.29 |
| 2020 | $14.35B | $1.60B | $4.26 |
| 2019 | $14.88B | $2.08B | $5.57 |
| 2018 | $13.60B | $3.55B | $9.50 |
| 2017 | $12.44B | $1.02B | $2.73 |
| 2016 | $11.32B | $1.65B | $4.40 |
| 2015 | $9.95B | $1.44B | $3.82 |
| 2014 | $9.68B | $515.00M | $1.36 |
| 2013 | $9.02B | $1.01B | $2.66 |
| 2012 | $8.66B | $1.30B | $3.41 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SYK's reported EPS growth of 7.3% a year over 13 years.
- EPS in 5 years
- $12.08
- Implied price
- $495.27
- Return from $275.43
- 12.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $246.24 — -10.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 29 | 35 | 41 | 47 | 53 |
|---|---|---|---|---|---|
| -2.7% | -4.9% | -1.2% | 2.0% | 4.8% | 7.3% |
| 2.3% | 0.0% | 3.9% | 7.2% | 10.2% | 12.9% |
| 7.3% | 4.9% | 8.9% | 12.5% | 15.6% | 18.4% |
| 12.3% | 9.8% | 14.0% | 17.7% | 21.0% | 23.9% |
| 17.3% | 14.7% | 19.1% | 22.9% | 26.3% | 29.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
75-43.63%Social Signal Score
Mentions (38)
- Newsseekingalpha.com·1d ago·Positive
Stryker: This Dividend Aristocrat Is Finally Cheap Again Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs. Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.
View source ↗ - Newsprnewswire.com·4d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Stryker to announce third quarter 2026 financial results Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial results.
View source ↗ - Newszacks.com·12d ago·Positive
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now? ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
View source ↗ - Newszacks.com·12d ago·Neutral
Can Stryker Vehicle Demand Support General Dynamics' Growth? GD's Stryker contract modification lifts cumulative value to $278.9M, supporting Land Systems demand through December 2028.
View source ↗ - Newszacks.com·12d ago·Positive
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
View source ↗ - Newsglobenewswire.com·12d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
View source ↗ - Newszacks.com·18d ago·Neutral
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
View source ↗ - Newsglobenewswire.com·19d ago·Positive
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™ New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle System and introducing Hoffmann®LRF smartHEX™ at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecy® Surgical Planning, which has su…
View source ↗ - News (RSS)seekingalpha·21d ago·Neutral
Stryker: Operational Issues Have Created An Opportunity
View source ↗ - Newsseekingalpha.com·22d ago·Negative
Stryker: Operational Issues Have Created An Opportunity Stryker's share price has declined significantly in recent months on the back of operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Despite headwinds, Stryker's growth is still solid and should rebound once the Vascular manufacturing issue is resolved. Further margin expansion is also an underappreciated part of the Stryker story.
View source ↗ - Newsbusinesswire.com·26d ago·Negative
Securities Fraud Investigation Into Stryker Corporation (SYK) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRYKER CORPORATION (SYK), CLICK HERE TO INQUIRE ABOUT PO…
View source ↗ - News (RSS)seekingalpha·27d ago·Positive
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·27d ago·Neutral
Stryker drops after comments on vascular and ortho segments
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)investing·27d ago·Neutral
Stryker Corporation stock hits 52-week low at 280.99 USD
View source ↗ - News (RSS)yahoo·31d ago·Positive
Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported.
View source ↗ - News247wallst.com·31d ago·Positive
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
View source ↗ - Newszacks.com·32d ago·Negative
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
View source ↗ - News (RSS)investing·34d ago·Neutral
Stryker completes first surgery using Apple Vision Pro app
View source ↗ - Newszacks.com·34d ago·Neutral
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center. Stryker received FDA De No…
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
SYK Looks 22.2% Undervalued on GF Value™ On August 31, 2026, Stryker Cor[+292 characters]
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode…
View source ↗ - News (RSS)businessinsider·39d ago·Neutral
Stryker to participate in the 2026 Wells Fargo Healthcare Conference <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on <b>Tuesday, September 8, 2026</b>, at the Encore Boston Harbor.Preston Wells, Vice President, Chief Financial...
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Stryker to participate in the 2026 Wells Fargo Healthcare Conference Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.
View source ↗ - Newszacks.com·40d ago·Neutral
Do Options Traders Know Something About Stryker Stock We Don't? Investors need to pay close attention to SYK stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
View source ↗ - Newsseekingalpha.com·46d ago·Neutral
Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
View source ↗ - News (RSS)investing·47d ago·Neutral
Thomas Kean Jr. trades in Alphabet, Amazon, and Stryker stocks
View source ↗ - News (RSS)seekingalpha·49d ago·Neutral
Stryker Corporation: Hold For Quality, Wait For The Dip
View source ↗ - News (Marketaux)seekingalpha.com·49d ago·Neutral
Stryker Corporation: Hold For Quality, Wait For The Dip (NYSE:SYK) Stryker Corporation: Hold For Quality, Wait For The Dip (NYSE:SYK)
View source ↗ - Newszacks.com·52d ago·Positive
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend? Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
View source ↗ - Newszacks.com·53d ago·Positive
Is SYK Worth Buying as Growth Improves but Execution Risks Persist? Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
View source ↗ - Newszacks.com·53d ago·Neutral
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half? Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.
View source ↗ - Newszacks.com·53d ago·Positive
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next? Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $3.56 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$3.69 vs $3.49beat
- Thu, Apr 30$2.60 vs $2.98miss
- Thu, Jan 29$4.47 vs $4.40beat
- Thu, Oct 30$3.19 vs $3.13beat
- Thu, Jul 31$3.13 vs $3.07beat
- Thu, May 1$2.84 vs $2.71beat
Estimates and results for SYK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SYK officers and directors.
- Bought
- $27k
- Sold
- $218.9m
5 trades
36 trades
- Crotty Dylan Bramsold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
- Stryker Ronda Esold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Keanhouse · NJ07 · disclosed Aug 19, 2026 (28d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Jul 16, 2026 (44d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Feb 20, 2026 (28d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (89d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 12, 2026 (33d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Dec 19, 2025 (29d later)Sell$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (32d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Oct 15, 2025 (33d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Sep 19, 2025 (25d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Aug 21, 2025 (21d later)Sell$15,001 - $50,000
- Thomas Keanhouse · NJ07 · disclosed Jul 17, 2025 (21d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$50,001 - $100,000
- Julie Johnsonhouse · TX32 · disclosed May 15, 2025 (38d later)Sell$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed May 12, 2025 (35d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.